Anchor lead: Why do people who’ve had organ transplants not respond well to Covid vaccines? Elizabeth Tracey reports

When someone has an organ transplant, they take lots of medicines to keep their body from attacking the new organ. Dorry Segev, a transplant surgeon at Johns Hopkins, and one author of a study looking at Covid vaccine response in these organ recipients, says that’s the key to their dampened antibody production after vaccination.

Segev: To prevent rejection in transplant patients we have to block the immune system. And it turns out one of the drugs that we use to block the immune system also happens to block the ability of the immune system to respond to the vaccine very well.  :12

Segev notes that this study was confined to the first vaccine dose.

Segev: If the response to dose two is as blunted as the response to dose one, maybe fifty percent of transplant patients will have protection but it’s quite certain that the majority will still not have protection.  :14

Segev says those who’ve received organ transplants should still get vaccinated and cautions that they must be extra vigilant in avoiding potential infection. At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: Transplant recipients may not respond well to Covid vaccines, Elizabeth Tracey reports

People who’ve received organ transplants don’t produce the antibody response to their first dose of an mRNA vaccine against Covid-19 seen in others, research by Dorry Segev, a transplant surgeon at Johns Hopkins, and colleagues has shown. Segev says that if the recipient was on a drug to prevent rejection called an antimetabolite, the response was even lower.

Segev: if we look at immunocompetent people, if you give them the first dose of the mRNA vaccine by two to three weeks afterwards nearly 100% of immunocompetent people will have an antibody response. What we found was in immunosuppressed transplant patients only 17% have an antibody response to dose one, and if you’re on an antimetabolite, only 8% have an immune response to dose one, and that is frightening.  :27

Segev says in the short term transplant recipients should be even more vigilant than ever regarding their exposure to Covid-19. At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: As drugs are developed for Alzheimer’s disease it seems clear that there is more than one type of this form of dementia, Elizabeth Tracey reports

Even as drugs that clear amyloid, a substance that accumulates in the brains of people with Alzheimer’s disease, continue being developed and studied, experts are questioning whether amyloid is the causative agent in the disease. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, says multiple causes likely exist, something called ‘heterogeneity.’

Lyketsos: Let’s get serious about deconstructing the heterogeneity that exists around this condition that we call dementia or Alzheimer’s dementia, and start understanding the drivers of dementia. Pretty clear that amyloid itself is not a direct driver of dementia. We’ve known that for a long time. It’s presence forecasts that you might get dementia but the amount of amyloid and the amount of dementia never have been well correlated. So my idea is the deconstruction of the heterogeneity.  :31

Lyketsos says most or even all diseases are highly individual, so a single agent to treat them is unlikely. At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: Are new drug trial results meaningful in Alzheimer’s disease? Elizabeth Tracey reports

A new drug that clears something called amyloid from the brain may delay progression of Alzheimer’s disease, recently released data indicate. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, says maybe.

Lyketsos: Maybe this drug is the right mechanism where amyloid reduction, which doesn’t work for any of the other drugs, might work for this drug. Because it somehow does the reduction more effectively. The phase two, we’ve seen those kinds of results a number of times, so let’s see.  :16

Lyketsos believes application may be limited.

Lyketsos: Maybe five or eight or ten percent of people with Alzheimer’s dementia are genetic overproducers of amyloid. You’d figure those were the people who would be helped by amyloid removal or reduction. First trial was put out a few months ago. Doesn’t seem to work.  :16

At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: What’s behind the use of many medicines in people with dementia? Elizabeth Tracey reports

How many medicines does an older person, and especially one with dementia, really need? A new study finds that 14% of those with dementia are taking medicines that affect the brain, and that can cause more falls and deaths. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, says this issue of too many medicines, or polypharmacy, needs more attention.

Lyketsos: There’s a huge debate about the value of statin medicines for 90 or 85 year old people without cardiovascular disease but with an elevated cholesterol if they really need to be on a statin. There’s also controversy about polypharmacy to manage blood pressure. In a much older person who has dementia, once you transition to having dementia there is a case to be made that you need a higher blood pressure to perfuse your vulnerable brain. So if you’re trying to manage the blood pressure to be lower, you might actually be causing more harm than good.  :32

Lyketsos says loved ones must advocate for those with dementia. At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: How often is someone with dementia overmedicated? Elizabeth Tracey reports

Polypharmacy refers to someone taking a multitude of medicines, with a recent study demonstrating that in people with dementia, polypharmacy with drugs that affect the brain occurs in 14%. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, says that’s concerning.

Lyketsos: As a doctor taking care of people with dementia I spend more time taking them off medicines than putting them on medicine. Medicines are generally not good for people with dementia especially an accumulation of medicines. They have vulnerable brains. And medicines additively impact the brain in unpredictable ways. Make it more likely that patients will fall. You know the total number of medicines that you’re on, if you have dementia, is a direct predictor of how likely you are to fall and break a hip.  :29

Lyketsos says use of medicines in people with dementia is often attempted to control behavioral symptoms, and that does not usually meet with success. He recommends beginning with a behavioral approach instead. At Johns Hopkins, I’m Elizabeth Tracey.


Anchor lead: Should specialized emergency departments exist for geriatric patients? Elizabeth Tracey reports

Emergency departments are frequently chaotic places, and for older people may make the experience of being in one traumatic. A recent study suggests that specialized EDs should be constructed just for elders, with a staff expert in recognizing and managing unique problems of aging. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, has a few questions.

Lyketsos: EDs and acute care hospitals are very bad places for people with dementia. The interesting question for me would be what’s the definition of geriatric? I’m not sure that a very healthy vigorous marathon running 85 year old is the same and needs a geriatric unit whereas you might have a very frail 55 year old with severe lung disease who is more like a geriatric patient in the lay perception. Is this really about age or is it about a frailty characteristic or cognitive impairment which would justify a very different approach.  :33

Lyketsos says study of such an initiative is appropriate. At Johns Hopkins, I’m Elizabeth Tracey.